Revenue and Profit - Revenue for the third quarter was RMB 570.18 million, a slight increase of 0.27% year-over-year[2] - Net profit attributable to shareholders for the third quarter was a loss of RMB 20.22 million, an improvement of 88.05% compared to the same period last year[2] - Total operating income decreased to 1,641,052,971.34 from 1,943,485,303.98, a reduction of 15.56%[13] - Net profit attributable to the parent company decreased to -163,809,859.67 from -128,013,309.46, a further loss of 27.96%[14] - Comprehensive income for the period was -154,937,680.21 yuan, with a net loss attributable to the parent company of -163,533,452.43 yuan[15] - Basic and diluted earnings per share were both -0.33 yuan[15] Assets and Liabilities - Total assets decreased by 4.72% to RMB 4.38 billion compared to the end of the previous year[2] - Total current assets decreased to 640,085,164.96 from 766,596,581.22, a decline of 16.50%[12] - Total non-current assets decreased to 3,744,665,689.92 from 3,835,570,170.12, a reduction of 2.37%[12] - Total liabilities decreased to 3,101,625,409.37 from 3,169,782,736.69, a decline of 2.15%[13] - Total assets decreased to 4,384,750,854.88 from 4,602,166,751.34, a reduction of 4.72%[13] Debt and Financing - The company's short-term debt decreased by 49.09% to RMB 527.17 million due to repayment of short-term loans[5] - Long-term debt increased significantly by 178.11% to RMB 954.42 million due to new long-term loans[5] - Financing activities cash flow decreased by 83.36% to a net inflow of RMB 57.61 million due to increased debt repayments[7] - Cash flow from financing activities was 57,610,655.52 yuan, a significant decrease from 346,167,921.18 yuan in the previous period[17] R&D and Government Subsidies - R&D expenses decreased by 50.13% to RMB 2.99 million as some R&D projects were completed[6] - Government subsidies increased by 33.65% to RMB 8.69 million due to new subsidies for the Guigang project[6] Cash Flow and Liquidity - Investment activities cash flow improved by 40.91% to a net outflow of RMB 287.31 million due to reduced spending on fixed assets[7] - The company's monetary funds at the end of the period were 193,090,330.02 yuan, a decrease from 252,666,166.60 yuan at the beginning of the period[11] - The company's financial report indicates a significant decrease in monetary funds, reflecting potential liquidity challenges[11] - Cash flow from operating activities was 234,487,961.21 yuan, a decrease from 215,734,213.51 yuan in the previous period[17] - Cash flow from investing activities was -287,305,326.58 yuan, an improvement from -486,251,894.02 yuan in the previous period[17] - Net cash received from sales of goods and services was 1,634,316,700.65 yuan, a decrease from 1,940,851,008.13 yuan in the previous period[16] - Cash paid for goods and services was 953,529,925.75 yuan, a decrease from 1,230,116,809.46 yuan in the previous period[17] - Cash paid to employees was 410,592,920.32 yuan, a decrease from 435,113,691.44 yuan in the previous period[17] - Cash and cash equivalents at the end of the period were 166,322,970.01 yuan, an increase from 157,961,221.92 yuan at the beginning of the period[17] Shareholders and Equity - The total number of ordinary shareholders at the end of the reporting period is 33,731[8] - Yang Yongping holds 21.57% of the shares, totaling 107,606,850 shares, with 80,705,137 shares under restricted conditions[8] - Zhejiang Yinwan Private Fund Management Co., Ltd. holds 3.76% of the shares, totaling 18,734,600 shares[8] - Merrill Lynch International holds 0.50% of the shares, totaling 2,472,475 shares[8] - Barclays Bank PLC holds 0.45% of the shares, totaling 2,221,800 shares[8] - The total number of restricted shares at the end of the period is 80,772,074, with no changes during the period[9] - The company's restricted shares are primarily due to executive lock-up regulations, with Yang Yongping holding 80,705,137 restricted shares[9] Accounts Receivable and Inventory - Accounts receivable increased to 38,452,229.83 from 33,480,424.15, reflecting a growth of 14.85%[12] - Inventory decreased to 380,976,017.10 from 442,863,402.45, a reduction of 13.97%[12] Operating Costs and Expenses - Total operating costs decreased to 1,812,691,932.39 from 2,071,147,739.78, a decline of 12.48%[13] - Minority interest in net loss decreased to 8,484,242.62 from 1,302,661.82, an increase of 551.38%[14] Management and Corporate Governance - Yang Yongping, the company's chairman and general manager, was released from detention on October 20, 2024, and has resumed his duties[10] Audit and Reporting - The company's third-quarter report was not audited[18]

| 证券代码：300511 | 证券简称：雪榕生物 公告编号：2024-076 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 上海雪榕生物科技股份有限公司 关于拟为子公司成都雪榕向成都银行申请综合授信提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 上海雪榕生物科技股份有限公司（以下简称"公司"）于2024年10月24日召开 第五届董事会第十五次会议，审议通过了《关于拟为子公司成都雪榕向成都银行申 请综合授信提供担保的议案》，具体情况如下： 一、担保情况概述 根据生产经营需要，公司全资子公司成都雪国高榕生物科技有限公司（以下简 称"成都雪榕"）拟向成都银行股份有限公司都江堰支行申请不超过 1,000 万元（含 1,000 万元）的综合授信。为支持子公司成都雪榕的经营发展，公司拟为上述综合授 信事项提供连带责任保证担保。 二、被担保人基本情况 1、公司名称：成都雪国高榕生物科技有限公司 7、经营范围：一般项目：生物化工产品技术研发；食用菌种植；技术服务、技 术开发、技术咨询、技术交流、技术转让、技术推广；货 ...

| 证券代码：300511 | 证券简称：雪榕生物 公告编号：2024-074 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 上海雪榕生物科技股份有限公司 第五届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会会议通知于 2024 年 10 月 14 日以电子邮件等通讯方式发出。 2、本次董事会于 2024 年 10 月 24 日在上海雪榕生物科技股份有限公司（以 下简称"公司"）会议室召开，采取现场和通讯相结合的方式进行表决。 3、本次会议应出席董事 7 人，实际出席董事 7 人。 4、本次董事会由董事长杨勇萍先生主持，公司监事、高级管理人员列席了 本次董事会。 5、本次董事会会议的召集、召开和表决程序符合《公司法》等法律、法规 及《公司章程》的有关规定，合法有效。 公司全资子公司成都雪国高榕生物科技有限公司（以下简称"成都雪榕"）根 据生产经营需要，决定向成都银行股份有限公司都江堰支行申请不超过 1,000 万 元（含 1,000 万元）的综合授信。 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 关于召开 2024 年第四次临时股东大会通知的公告 上海雪榕生物科技股份有限公司（以下简称"公司"）第五届董事会第十五 次会议审议通过了《关于召开 2024 年第四次临时股东大会的议案》，决定于 2024 年 11 月 15 日召开公司 2024 年第四次临时股东大会，现将本次股东大会的有关 事项通知如下： 一、本次股东大会召开的基本情况 | 证券代码：300511 | 证券简称：雪榕生物 | 公告编号：2024-077 | | --- | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | | 上海雪榕生物科技股份有限公司 5、会议的召开方式：本次股东大会采取现场表决与网络投票相结合的方式。 （1）现场投票：股东本人出席现场会议或通过授权委托他人出席现场会议； 1、股东大会届次：2024 年第四次临时股东大会。 2、股东大会召集人：公司董事会。 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》等规定。 4、会议召开的日期、 ...

证券代码：300511 证券简称：雪榕生物 公告编号：2024-073 债券代码：123056 债券简称：雪榕转债 2024年10月20日，公司收到相关部门的《解除留置通知书》，杨勇萍先生已解除 留置措施，杨勇萍先生已能正常履行公司董事长及总经理的职责，陆勇先生、郑伟 东先生将不再代为履行相关职责。 公司指定的信息披露媒体为《上海证券报》及巨潮资讯网，公司发布的信息均以 在上述媒体披露的信息为准。 特此公告。 上海雪榕生物科技股份有限公司 董事会 上海雪榕生物科技股份有限公司 关于公司控股股东、董事长、总经理解除留置的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 上海雪榕生物科技股份有限公司（以下简称"公司"）于2024年6月11日披露了《关 于公司控股股东、董事长、总经理被留置的公告》（公告编号：2024-047）。 2024年10月21日 1 ...

1、雪榕转债（债券代码：123056）转股期限为2021年1月4日至2026年6月23日， 最新有效的转股价格为4.10元/股。 2、2024年第三季度，共有610张"雪榕转债"完成转股（票面金额共计61,000元 人民币），合计转为14,680股"雪榕生物"股票（股票代码：300511）。 3、截至2024年第三季度末，公司剩余可转债为5,838,505张，剩余票面总金额为 583,850,500元人民币。 | 证券代码：300511 | 证券简称：雪榕生物 公告编号：2024-072 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 上海雪榕生物科技股份有限公司 2024年第三季度可转换公司债券转股情况公告 本公司及除董事长杨勇萍先生外的董事会成员保证信息披露内容的真实、准 确和完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 2024年第三季度，"雪榕转债"因转股减少610张，转股数量为14,680股。截至 2024年9月30日，"雪榕转债"尚有5,838,505张，剩余可转债票面金额为583,850,500 元人民币。公司股份变动情况如下： | 股份性质 | ...

国投证券股份有限公司 关于上海雪榕生物科技股份有限公司 2024 年半年度跟踪报告 2 | 公司及股东承诺事项 | 是否履 行承诺 | 未履行承诺的原因及解决措施 | | --- | --- | --- | | 1．股东关于所持股份自愿锁定及期后减持约 | 是 | 不适用 | | 束的承诺 | | | | 2．公司、控股股东及实际控制人、持股 5%以上 | 是 | 不适用 | | 股东关于回购股份及赔偿投资者损失的承诺 | | | | 3．持有发行人 5%以上股份的股东关于持股意 | 是 | 不适用 | | 向及减持意向的承诺 | | | | 4．关于填补被摊薄即期回报的承诺 | 是 | 不适用 | | 5．公司关于利润分配政策的承诺 | 是 | 不适用 | | 6．关于避免同业竞争的承诺 | 是 | 不适用 | | 7．关于减少及规范关联交易的承诺 | 是 | 不适用 | | 8．关于补缴社会保险和住房公积金的承诺 | 是 | 不适用 | | 9．关于股权激励的承诺 | 是 | 不适用 | | 保荐人名称：国投证券股份有限公司 | 被保荐公司简称：雪榕生物（300511） | | --- | --- | | ...

China Chengxin International Credit Rating Co.,Ltd. [2024]331 中诚信国际关于关注上海雪榕生物科技股份有限公司 中诚信国际认为，公司 2021~2023 年连续三年出现亏损，2024 年上半年生 产经营情况未有好转且继续亏损，虽然 7 月以来食用菌价格已好于去年同期， 加之四季度销售旺季支撑，预计下半年食用菌价格或将有所回升，但短期内盈利 指标难以大幅改善；同时，公司控股股东、董事长、总经理杨勇萍先生被留置， 北京市东城区朝阳门内大街南竹杆胡同 2 号银河 SOHO5 号楼 邮编：100010 电话：（8610）6642 8877 传真：（8610）6642 6100 Building 5, Galaxy SOHO, No.2 Nanzhuganhutong,ChaoyangmenneiAvenue, Dongcheng District,Beijing, 100010 而相关债权银行消化该事件需要时间，截至 2024 年 8 月末，公司尚未使用的银 行授信额度约 15 亿元，信用状况仍有待改善。中诚信国际将持续关注在产品价 格回升预期下后续公司的业 ...

| 证券代码：300511 | 证券简称：雪榕生物 公告编号：2024-071 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 上海雪榕生物科技股份有限公司 关于预计触发转股价格向下修正条件的提示性公告 本公司及除董事长杨勇萍先生外的董事会成员保证信息披露内容的真实、准 确和完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、证券代码：300511 证券简称：雪榕生物 2、债券代码：123056 债券简称：雪榕转债 3、转股价格：4.10元/股 4、转股期限：2021年1月4日至2026年6月23日 5、根据上海雪榕生物科技股份有限公司（以下简称"公司"）《创业板公开发 行可转换公司债券募集说明书》（以下简称"《募集说明书》"）的规定：在本次发 行的可转换公司债券存续期间，当公司股票在任意连续三十个交易日中至少有十五 个交易日的收盘价低于当期转股价格的85%时，公司董事会有权提出转股价格向下 修正方案并提交公司股东大会表决。 经深交所"深证上[2020]637号"文同意，公司58,500万元可转债于2020年7月24 日起在深交所挂牌交易，债券简称"雪榕转债"， ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2024, with total revenue reaching CNY 500 million, representing a 25% growth compared to the same period in 2023[7]. - The company's operating revenue for the first half of 2024 was ¥1,070,868,016.87, a decrease of 22.11% compared to the same period last year[12]. - The net profit attributable to shareholders was a loss of ¥143,594,085.68, representing a decline of 449.04% year-on-year[12]. - The net profit after deducting non-recurring gains and losses was a loss of ¥156,485,398.79, down 476.18% from the previous year[12]. - The net cash flow from operating activities was ¥68,864,243.03, a decrease of 70.44% compared to the same period last year[12]. - The company achieved operating revenue of CNY 1,070.87 million, a year-on-year decrease of 22.11%, and a net profit attributable to shareholders of CNY -143.59 million[22]. - The company reported a net loss attributable to shareholders for the first half of 2024, continuing a trend of losses for three consecutive years from 2021 to 2023[44]. - The company reported a significant increase in user data, with a total of 75,000 new users added in the last quarter[69]. Future Outlook - The company has provided a positive outlook for the second half of 2024, projecting a revenue growth of 20% year-over-year, aiming for a total revenue of CNY 1 billion by the end of the year[7]. - New product launches are expected to contribute an additional CNY 100 million in revenue, with the introduction of two new mushroom varieties in Q3 2024[7]. - The company is expanding its market presence, targeting a 10% increase in market share in the Southeast Asia region by the end of 2024[7]. Research and Development - Research and development expenses have increased by 18%, focusing on innovative cultivation techniques and product diversification[7]. - Research and development investment decreased by 37.70% to ¥2,251,021.28 from ¥3,613,127.10 in the previous year[31]. - The company has been selected as a key laboratory for mushroom strain research by the Ministry of Agriculture and Rural Affairs, highlighting its research capabilities[28]. Risks and Challenges - The company has identified risks including market competition and raw material price fluctuations, which may impact profit margins[2]. - The company faces risks from increased competition in the edible mushroom market, which may lead to price declines and impact profit margins[46]. - Seasonal fluctuations in sales prices and profits are evident, with higher prices typically in Q1 and Q4, while Q2 and Q3 see lower prices due to increased supply of fresh vegetables[47]. Financial Position - The total assets at the end of the reporting period were ¥4,699,251,971.22, an increase of 2.11% from the end of the previous year[12]. - The net assets attributable to shareholders decreased by 9.23% to ¥1,411,073,724.90 compared to the end of the previous year[12]. - The company's total liabilities decreased by 5.96% in short-term borrowings, which amounted to ¥777,068,655.56 at the end of the reporting period[34]. - The company's asset-liability ratio exceeded 70%, with current liabilities surpassing current assets by 780.55 million yuan, indicating liquidity concerns[44]. Shareholder Information - No cash dividends or stock bonuses will be distributed to shareholders for the current fiscal year, as the company aims to reinvest profits into growth initiatives[2]. - The company held its first extraordinary shareholders' meeting on March 28, 2024, with a participation rate of 25.73%[50]. - The annual shareholders' meeting took place on May 17, 2024, with a participation rate of 27.65%[50]. Corporate Governance - The company emphasizes the importance of risk awareness for investors, particularly regarding future plans and projections[2]. - The company has not experienced any major natural disasters or food safety incidents during the reporting period[73]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[56]. Production and Operations - The company has a daily production capacity of 1,710 tons of edible mushrooms, with 1,275 tons of that being enoki mushrooms, ranking first in the country[25]. - The company has established comprehensive edible mushroom factories in multiple regions including Jilin, Shandong, and Thailand[16]. - The company operates a unified procurement model for raw materials, primarily sourcing agricultural by-products, which reduces dependency on suppliers[24]. Accounting and Financial Reporting - The financial statements were approved by the board of directors on August 28, 2024[120]. - The financial statements comply with the requirements of the enterprise accounting standards, accurately reflecting the financial position as of June 30, 2024, and the operating results and cash flows for the first half of 2024[125]. - The company has established specific accounting policies and estimates based on its actual production and operational characteristics, including provisions for bad debts exceeding RMB 2 million and construction in progress exceeding RMB 9 million[129].